2型糖尿病非胰岛素类新型药物临床应用研究新进展  

New Progress in Clinical Application of New Non-insulin Drugs for Type 2 Diabetes

作　　者：蒋一凡 王科斯 张新 JIANG Yifan;WANG Kesi;ZHANG Xin(Department of Endocrinology,Liaoyou Gem Flower Hospital,Panjin,Liaoning Province,124099 China)

机构地区：[1]盘锦辽油宝石花医院内分泌科,辽宁盘锦124099

出　　处：《糖尿病新世界》2022年第19期190-194,198,共6页Diabetes New World Magazine

摘　　要：2型糖尿病是我国糖尿病患者发病最广分型,其发病率逐年升高,并呈现出发病人群年轻化、多种病变并发症等特点,为患者和社会带来沉重的医疗负担。传统糖尿病治疗方案主要为胰岛素治疗,然而胰岛素治疗通常伴有低血糖、胰岛素过敏、水肿等不良反应。在此背景下,基于靶点作用机制的非胰岛素类药物的研究开发为2型糖尿病患者提供了新的治疗选择方案。相关研究表明:新型非胰岛素类药物除高效降糖效果外,兼具心肾保护作用,对糖尿病并发症具有显著预防作用。鉴于此,本文在梳理2型糖尿病的发病机理的基础上,对非胰岛素类降糖药物的近期临床研究进展开展综述,以期为广大医务工作者、药物研发人员提供有益参考。Type 2 diabetes is the most common type of diabetes in our country,and its incidence rate is increasing year by year,and it presents the characteristics of younger onset population and multiple disease complications,which brings a heavy medical burden to patients and society.The traditional treatment of diabetes is mainly insulin treatment,but insulin treatment is usually accompanied by adverse reactions such as hypoglycemia,insulin allergy,and edema.In this context,the research and development of non-insulin drugs based on the target mechanism of action provides new treatment options for patients with type 2 diabetes.Relevant studies have shown that the new noninsulin drugs not only have high hypoglycemic effects,and have a significant preventive effect on diabetic complications.In view of this,this paper reviews the recent clinical research progress of non-insulin hypoglycemic drugs on the basis of sorting out the pathogenesis of type 2 diabetes,in order to provide useful reference for the majority of medical workers and drug research and development personnel.

关 键 词：2型糖尿病 非胰岛素类药物 降糖 心肾保护 获益效应 

分 类 号：R587.1[医药卫生—内分泌]